These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24867590)

  • 1. Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine.
    Weiss JT; Dawson JC; Fraser C; Rybski W; Torres-Sánchez C; Bradley M; Patton EE; Carragher NO; Unciti-Broceta A
    J Med Chem; 2014 Jun; 57(12):5395-404. PubMed ID: 24867590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach.
    Weiss JT; Dawson JC; Macleod KG; Rybski W; Fraser C; Torres-Sánchez C; Patton EE; Bradley M; Carragher NO; Unciti-Broceta A
    Nat Commun; 2014; 5():3277. PubMed ID: 24522696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
    Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
    J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor.
    Rubio-Ruiz B; Weiss JT; Unciti-Broceta A
    J Med Chem; 2016 Nov; 59(21):9974-9980. PubMed ID: 27786474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
    Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
    Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-specific activation of gemcitabine by endogenous H
    Maiti M; Yoon SA; Cha Y; Athul KK; Bhuniya S; Lee MH
    Chem Commun (Camb); 2021 Sep; 57(75):9614-9617. PubMed ID: 34486009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
    Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
    J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
    Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
    Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
    Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
    Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-mediated targeting of polymeric conjugates of gemcitabine.
    Cavallaro G; Licciardi M; Salmaso S; Caliceti P; Gaetano G
    Int J Pharm; 2006 Jan; 307(2):258-69. PubMed ID: 16298091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
    Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
    J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules.
    Stella B; Arpicco S; Rocco F; Marsaud V; Renoir JM; Cattel L; Couvreur P
    Int J Pharm; 2007 Nov; 344(1-2):71-7. PubMed ID: 17651931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy.
    Weiss JT; Carragher NO; Unciti-Broceta A
    Sci Rep; 2015 Mar; 5():9329. PubMed ID: 25788464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
    Alexander RL; Greene BT; Torti SV; Kucera GL
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.
    Catarata R; Azim N; Bhattacharya S; Zhai L
    J Mater Chem B; 2020 Apr; 8(14):2887-2894. PubMed ID: 32191246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.